Business Wire

Crayon Expands Strategic Partnership With Workplace From Facebook

13.10.2020 09:00:00 EEST | Business Wire | Press release

Share

Crayon, a global leader in digital transformation, today announced it is expanding its partnership with Workplace from Facebook to change the way organizations communicate and get work done. Crayon has offered Workplace, a business collaboration tool, in the Nordics since 2018 and this new agreement will expand the partnership into 20 more countries over the next year.

Crayon has seen an increase in the need for collaborative tools as companies around the world shifted to a new approach to work, connecting a more remote and distributed workforce. The expanded partnership means Crayon and Workplace will help organizations work closer together, break down communication silos and enable stronger company culture, especially with remote and frontline workers by providing a unified system of engagement and collaboration.

“This partnership means we can help more companies to connect on one platform so that everyone feels like they have a voice in the organization,” said Crayon co-founder Rune Syversen. “We understand the challenge of the connected company has nothing to do with technology, it has to do with changing the culture toward open collaboration. Our Workplace program is about just that – helping our customers to leverage the benefits of the Workplace platform emphasizing cultural changes. Since we started this partnership, we’ve observed Workplace becoming our fastest growing tech partner, particularly as the technology works well with the Microsoft IT stack. For us, along with Workplace, it’s not just another IT implementation, it is an introduction of a whole new way of communicating across the entire company.”

Crayon has helped deploy Workplace at all types of organizations, from healthcare companies to transportation organizations globally.

“Our employees have different workspaces, some are working from their office, others are working from a farm. We needed a way to communicate with everyone across the organization regardless of where or how they did their job and Workplace made that possible,” said Meylin S. Loo, Digital Communications Chief for Tine in Norway.

“Also, for us it was important to have a partner that had implemented this solution before to give us crucial guidance on best practices. Plus, we already have a long-standing successful relationship with Crayon and so we knew they were the right one to help us implement Workplace.”

Among the 20 countries that Crayon and Workplace will expand to include Norway, Denmark, Sweden, Finland, the UK, France and the US.

“We are proud to expand our partnership with Crayon, which has dozens of joint Workplace customers and has added their technical expertise to each launch to enable wall-to-wall adoption of Workplace across every employee in an organization. This deepened partnership and new growth trajectory is another important milestone on our two companies’ journeys. Right now companies around the world are trying to keep their workforces connected, engaged and keep their employees informed, and we believe that Workplace is a perfect solution for many of today’s real-world challenges,” said Julien Codorniou, VP, Workplace from Facebook.

About Crayon:

Crayon helps customers build the commercial and technical foundation for a successful digital transformation journey through a reliable services framework allowing our customers to right-size and optimize their IT estates. Headquartered in Oslo, Norway, Crayon has over 1600 employees across more than 50 locations worldwide.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Melanie Coffee
PR and Media Relations Director
Melanie.coffee@crayon.com
+47 46 74 8648

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye